[go: up one dir, main page]

FI20011542L - Use of male sognase gene amplification - Google Patents

Use of male sognase gene amplification

Info

Publication number
FI20011542L
FI20011542L FI20011542A FI20011542A FI20011542L FI 20011542 L FI20011542 L FI 20011542L FI 20011542 A FI20011542 A FI 20011542A FI 20011542 A FI20011542 A FI 20011542A FI 20011542 L FI20011542 L FI 20011542L
Authority
FI
Finland
Prior art keywords
gene amplification
sognase
male
carcinomas
relates
Prior art date
Application number
FI20011542A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI20011542A0 (en
Inventor
Merja Helenius
Merja Saramaeki
Marika Linja
Teuvo Tammela
Tapio Visakorpi
Original Assignee
Fit Biotech Oyj Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fit Biotech Oyj Plc filed Critical Fit Biotech Oyj Plc
Priority to FI20011542A priority Critical patent/FI20011542L/en
Publication of FI20011542A0 publication Critical patent/FI20011542A0/en
Priority to PCT/FI2002/000636 priority patent/WO2003006690A1/en
Publication of FI20011542L publication Critical patent/FI20011542L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to the use of urokinase gene amplification as a marker for evaluating the treatment sensitivity and specificity of carcinomas, especially invasive forms of carcinomas, and in particular invasive forms of hormone-dependent cancers, such as prostate cancer and breast cancer. The present invention also relates to methods of identification of carcinomas profiled by urokinase gene amplification.
FI20011542A 2001-07-13 2001-07-13 Use of male sognase gene amplification FI20011542L (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FI20011542A FI20011542L (en) 2001-07-13 2001-07-13 Use of male sognase gene amplification
PCT/FI2002/000636 WO2003006690A1 (en) 2001-07-13 2002-07-15 Use of urokinase gene amplification as a marker

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20011542A FI20011542L (en) 2001-07-13 2001-07-13 Use of male sognase gene amplification

Publications (2)

Publication Number Publication Date
FI20011542A0 FI20011542A0 (en) 2001-07-13
FI20011542L true FI20011542L (en) 2003-01-14

Family

ID=8561659

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20011542A FI20011542L (en) 2001-07-13 2001-07-13 Use of male sognase gene amplification

Country Status (2)

Country Link
FI (1) FI20011542L (en)
WO (1) WO2003006690A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2886946B1 (en) * 2005-06-09 2007-08-10 Biomerieux Sa METHOD FOR THE DIAGNOCTIC / PROGNOSTIC OF BREAST CANCER

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422090A (en) * 1984-08-13 1995-06-06 Biotechnology Australia, Pty., Ltd. Human PAI-2
JP3653469B2 (en) * 1997-11-25 2005-05-25 ジェネンテック・インコーポレーテッド Fibroblast growth factor-19

Also Published As

Publication number Publication date
FI20011542A0 (en) 2001-07-13
WO2003006690A1 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
WO2001051628A3 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2001060860A3 (en) Genes differentially expressed in human prostate cancer and their use
HK1148783A1 (en) Gene expression markers for breast cancer prognosis
WO2003072125A8 (en) Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2003009814A3 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2001070979A3 (en) Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
MXPA03003281A (en) Non-invasive enzyme screen for tissue remodelling-associated conditions.
ATE423191T1 (en) PROSTATE STEM CELL ANTIGEN (PSCA) AND ITS USES
EP1893196A4 (en) DIARYLHYDANTOINE COMPOUNDS
WO2005123993A3 (en) Phage microarray profiling of the humoral response to disease
WO2006095086A8 (en) Traceability of cellular cycle anomalies targeting oncology and neurodegeneration
WO2006028655A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
MXPA05008794A (en) Glycorpotein antigen sima135 expressed in metastatic human tumor cells.
WO2005053604A3 (en) Antibodies specific for cancer associated antigen sm5-1 and uses thereof
HUP0303649A2 (en) Liposome targeting of matrix metalloproteinase inhibitors
EP1377596A4 (en) Ttk in diagnosis and as a therapeutic target in cancer
DK1485345T3 (en) Urokinase Inhibitors, Their Preparation and Use
FR2875601B1 (en) VIMENTIN PHOSPHORYLEE AS A MARKER OF AGGRESSIVITY AND / OR INVASIVENESS OF TUMORS
WO2001046697A3 (en) Identification, assessment, prevention, and therapy of breast cancer
EP1451552A4 (en) Reagents and methods useful for detecting diseases of the breast
WO2004031402A3 (en) Methylation profile of cancer
WO2002046765A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
TW200517122A (en) Antibodies specific for cancer associated antigen SM5-1 and uses thereof